Top Markets
#1 DogBull DogBull +75.07%
#2 Siren Siren +31.73%
#3 Verus Coin Verus Coin +18.65%
#4 OriginTrail OriginTrail +14.62%
#5 龙虾 (Lobster) 龙虾 (Lobster) +11.73%
#6 Tutorial Tutorial +7.87%
#7 COTI COTI +7.71%
#8 Unit Pump Unit Pump +7.21%
#9 Pump.fun Pump.fun +7.21%
#10 PulseChain PulseChain +6.89%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Brii Biosciences Limited Brii Biosciences Limited

Brii Biosciences Limited

2137
Rank in Stocks #22138
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a... Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Share Price
$0.12984512
Last synced: 2026-08-21
Market Cap
$93.64M
Change (1 day)
3.57%
Change (1 year)
-49.27%
Country
CN
Trade Brii Biosciences Limited (2137)

Category

Healthcare
P/E ratio for Brii Biosciences Limited (2137)
P/E ratio as of 2026 TTM: 0
According to Brii Biosciences Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Brii Biosciences Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.